His research established that dendritic cells are responsible for imprinting the tissue-specific homing of T lymphocytes.

He is currently Executive Director of Fundacion Ciencia para la Vida (FCV),[1] a non profit institution that carries out scientific and technological research.

In 1997 he joined the Fundación Ciencia para la Vida acting as its first Executive Director.

During his years at the Boston Biomedical Research Institute Dr. Rosemblatt was the first to publish a report on the use of monoclonal antibody technology to study muscle physiology.

The main aspects of his research deals with studies related to the function of regulatory T cells.